Stay updated on Checkpoint Inhibitor+Chemoradiation in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Checkpoint Inhibitor+Chemoradiation in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Checkpoint Inhibitor+Chemoradiation in Head and Neck Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating an update in the information related to the phase II non-randomized trial studying the safety and efficacy of combining the PD-1 inhibitor pembrolizumab with standard chemoradiation for locally advanced non-nasopharyngeal head and neck cancer.
    Difference
    0.0%
    Check dated 2024-06-06T14:31:18.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients, specifying the types of cancer, disease stages, and health conditions required for participation. Previously, this section only indicated that no information was provided.
    Difference
    14%
    Check dated 2024-05-22T20:28:48.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:32:53.000Z thumbnail image

Stay in the know with updates to Checkpoint Inhibitor+Chemoradiation in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Checkpoint Inhibitor+Chemoradiation in Head and Neck Cancer Clinical Trial page.